Vinblastine is an antimicrotubule drug used in the treatment of various kinds of cancer. Cancers that respond to the administration of this drug as part of a controlled chemotherapy regimen are Hodgkins Lymphoma, non-small cell lung cancer, head and neck cancer, breast cancer, and testicular cancer. It has also had success in the treatment of Langerhans Histiocytosis, an affliction of the cells in the Isles of Langerhans, which is in the pancreas.
Vinblastine has several interesting chemical properties in it's application as a chemotherapy drug regimen. In low dosage concentrations, it suppresses microtubule dynamics, which would be the microtubules' ability to form and guide copied chromosomes to new cells in the mitotic cell cycle. In high dosage concentrations, it reduces microtubules polymer mass, making them weak and ineffective in guiding the copied chromosomes to their designated destinations. Recent findings support and indicate vinblastine plays an important part in stimulating microtubules minus-end detachment from their organizing centers, making it harder for them to establish and construct themselves.
The benefit to society, of course, would be that vinblastine is an effective chemotherapy drug, one that helps eradicate cancer cells by destroying the formation of those cancer cells within the confines of their reproductive cell cycle.